NAD+
Nicotinamide adenine dinucleotide · cellular redox cofactor
Essential cellular redox cofactor and signaling substrate widely marketed for energy and longevity, while direct IV NAD+ wellness outcomes remain insufficiently established.
Reference dose
50–250 mg
Source-specific educational reference, not an individualized recommendation.
Reference schedule
2–3× weekly · 2–12 weeks
New to peptide research?
This page gets detailed quickly.
Profiles include evidence, formats, units, source-specific reference amounts and, where relevant, device details. If any of those terms are unfamiliar, do not guess your way through them. Start with a Personalised Guide and we will put the foundations in the right order for you.
At a glance
What it is
Cellular cofactor
NAD+ participates in redox chemistry and enzyme signaling throughout human cells.
Direct IV outcomes
Not established
A 2026 systematic review found no eligible IV/IM NAD+ wellness outcomes trials.
Human precursor evidence
More developed
NR/NMN can raise NAD-related biomarkers, but they are separate compounds from IV NAD+.
Regulatory status
No approved wellness use
NAD is on FDA's 503A Category 1 list under evaluation, which is not drug approval.
What it is
NAD+ stands for nicotinamide adenine dinucleotide, a small non-peptide molecule present in every living cell. It cycles between oxidized NAD+ and reduced NADH forms during energy metabolism.
Beyond redox chemistry, NAD+ is consumed by enzymes such as sirtuins, PARPs and CD38, linking it to DNA-repair responses, cell signaling and metabolic regulation.
Research focus
How it works
NAD+ is an essential cofactor in oxidation-reduction reactions and a substrate for enzymes including sirtuins, PARPs and CD38. Cellular NAD biology is fundamental, but raising NAD-related metabolites does not automatically translate into proven anti-aging, energy or disease outcomes.
Important context
Direct NAD+ infusion, oral NAD-boosting precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and endogenous cellular NAD+ are related but not interchangeable evidence categories. Human precursor trials cannot simply be cited as proof that IV NAD+ produces the same clinical effects.
What it is studied for
Ageing research examines whether declining tissue NAD availability contributes to age-associated metabolic and functional changes.
Metabolic and mitochondrial research explores whether raising NAD-related metabolites can improve cellular energetics, vascular function, insulin sensitivity or other physiological endpoints.
Wellness clinics use IV NAD+ for proposed energy, recovery, cognition or longevity benefits, but these direct infusion claims have much less outcome evidence than the underlying cellular biology.
More contextThe biology is strong; the direct IV wellness evidence is weakSee the deeper context, evidence details and practical distinctions behind this profile.
A 2026 systematic review identified 33 human NAD-related intervention studies, mostly involving oral precursors. It found consistent biochemical target engagement for NR and NMN but heterogeneous or null clinical outcomes across many healthspan endpoints.
That same review found no eligible clinical-outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness. Direct IV NAD+ evidence consists mainly of small pharmacokinetic and short-term tolerability studies.
- A 2019 pilot infused NAD+ over six hours and measured plasma/urine NAD metabolites; it was a pharmacokinetic study rather than a clinical efficacy trial.
- A 2026 retrospective commercial-clinic study compared four consecutive days of 500 mg IV NAD+ with IV NR and found substantially more infusion symptoms with NAD+, including gastrointestinal symptoms, increased heart rate and chest pressure.
- FDA lists NAD as a 503A Category 1 bulk substance under evaluation; that status is not FDA approval of NAD+ injection for wellness or anti-aging.
- FDA has warned compounders after adverse-event reports linked to injectable NAD+ products made from unsuitable food-grade ingredients, with reactions consistent with endotoxin exposure.
Why people are interested
What makes NAD+ worth researching.
Established biology
Fundamental cellular role
NAD+/NADH redox cycling is central to metabolism and mitochondrial ATP production, while NAD+ also serves as a substrate for enzymes involved in DNA repair, signaling and stress responses.
Human precursor trials
Biochemical target engagement
Human studies of NR and NMN generally show that NAD-related biomarkers can be increased, establishing biological activity without proving broad anti-aging or performance benefits.
Limited direct human evidence
Direct IV NAD+ evidence
Human IV NAD+ studies remain small and focus mainly on pharmacokinetics, metabolism and short-term tolerability rather than clinically meaningful anti-aging or wellness outcomes.
FDA safety warning
Sterile-compounding risk
FDA has specifically warned about unsuitable food-grade NAD+ ingredients used for sterile compounding after reports of severe infusion reactions consistent with endotoxin contamination.
Evidence
Where the evidence is strongest, and what kind of evidence it is.
Human + preclinical evidence synthesis
2026 systematic review
Thirty-three human NAD-related intervention studies were included. Oral precursor target engagement was consistent, but healthspan-relevant clinical effects were heterogeneous and direct IV/IM NAD+ outcomes trials for wellness were absent.
Human · small pharmacokinetic study
2019 IV NAD+ pilot
Eight participants received a six-hour NAD+ infusion and three received saline. The study documented plasma and urinary NAD-related metabolites but was not designed to test clinical anti-aging, energy or disease outcomes.
Human · retrospective tolerability
2026 real-world IV study
Commercial-clinic records showed moderate-to-severe gastrointestinal symptoms, increased heart rate and chest pressure during 500 mg NAD+ infusions, with symptoms resolving after infusion.
Human · separate compounds
NR/NMN precursor trials
NR and NMN often raise NAD-related biomarkers and are generally tolerated in short-term trials, but functional and metabolic outcomes are inconsistent and cannot be treated as direct IV NAD+ evidence.
Human research
The strongest human NAD-augmentation literature involves oral precursors such as NR and NMN rather than direct NAD+ infusion. These studies usually demonstrate biomarker changes more consistently than clinically meaningful health improvements.
A 2019 direct IV NAD+ pilot characterized metabolism during a six-hour infusion but did not test anti-aging or wellness outcomes.
A 2026 retrospective study of commercial IV use found substantially more infusion-related symptoms with NAD+ than IV NR, including gastrointestinal symptoms, increased heart rate and chest pressure; it was not a randomized efficacy trial.
A 2026 systematic review concluded that clinical effectiveness of NAD+ augmentation for anti-aging and wellness remains inconclusive and found no eligible direct IV or IM NAD+ outcomes trials for those indications.
Preclinical research
Animal and cellular studies show broad biological effects from manipulating NAD metabolism across mitochondrial function, metabolic disease, inflammation, vascular biology and ageing-related pathways.
Preclinical benefits are generally stronger and more consistent than current human functional-outcome data.
Different NAD-boosting strategies can have different uptake, metabolism and tissue effects, so findings from one precursor or route should not automatically be assigned to another.
Reference dosing
Reference amount, schedule and conversion.
A reference amount is only useful when you know the formulation, concentration and delivery device it belongs to. Do not transfer a vial amount into a pen, a pen click count into another pen, or a syringe-unit number into a different concentration.
01
Identify the format
Vial, reusable cartridge pen, prefilled multi-dose pen or single-dose autoinjector.
02
Confirm concentration
Know the total peptide amount and liquid volume or the manufacturer/vendor concentration.
03
Understand the units
Keep mg/mcg, mL and syringe units or device clicks separate.
04
Then use the reference
Only convert a known reference amount with the calculator that matches the actual device.
Source-specific reference
50–250 mg
2–3× weekly · 2–12 weeks
The 50–250 mg range is a Pep Report research reference. NAD+ protocols vary by route, formulation, infusion rate and research context.
Calculator connection
This profile does not currently use a vial or pen calculator. Follow the formulation-specific information shown for the product or reference you are using.
For IV NAD+, concentration and infusion rate both matter, and sterile-product quality is a central safety issue. The generic peptide vial calculator is intentionally disabled because it does not model infusion rate, solution suitability, endotoxin risk or route-specific clinical monitoring.
Storage
Start with the format. Then verify the exact product.
Rule of thumb, not a product instruction
Storage belongs to the exact formulation. Generic advice can orient you, but the label, pharmacy directions or formulation-specific stability data should determine the final temperature and usable-life limits.
Pens
Treat a pen as a finished drug-device product: protect it from unnecessary heat and light, do not freeze unless the exact label explicitly permits it, and use that device's own unopened and in-use storage window.
Vials
Treat dry and reconstituted vials as different stability states. Refrigeration after mixing is common for some formulations but is not a universal peptide rule.
Product-specific notes
There is no single FDA-approved NAD+ infusion product label defining a universal storage standard for wellness use.
Sterile compounded products require pharmacy-specific handling, beyond-use dating and storage based on validated formulation and sterility practices.
Practical reference
Formats
Endogenous cellular cofactor
Compounded IV products
NAD-boosting precursors are separate compounds
Reconstitution & units
IV NAD+ should not be treated like a peptide research vial. Sterile formulation suitability, diluent, final concentration, infusion conditions and source-material quality are all clinically relevant.
FDA has specifically cautioned against using food-grade NAD+ as an ingredient for sterile injectable compounding.
IV protocols may be described in mg, concentration and infusion rate; these are separate variables.
The generic peptide vial calculator is disabled because it does not model infusion rate, sterile-product quality or route-specific administration requirements.
Safety, status & open questionsOpen the practical cautionsNAD+ is a normal and essential molecule in human biology, but there is no FDA-approved NAD+ infusion for anti-aging, energy, longevity or general wellness. Compounded IV NAD+ and oral NAD precursors should be evaluated as distinct products with distinct evidence.
Open questions
There is no established FDA-approved anti-aging, longevity, cognition, energy or general-wellness indication for direct NAD+ infusion.
The optimal route, amount, infusion rate and treatment frequency for proposed wellness uses are not established by high-quality clinical outcomes trials.
NR, NMN, niacin, nicotinamide and direct NAD+ are metabolically related but are not pharmacologically interchangeable interventions.
Long-term safety and clinically meaningful benefit from repeated high-dose IV NAD+ remain inadequately characterized.
Regulatory notes
NAD+ is not FDA approved as an IV drug for anti-aging, longevity, energy or general wellness.
As of April 2026, nicotinamide adenine dinucleotide (NAD) appears in FDA's 503A Category 1 list of bulk drug substances under evaluation. Category 1 status is not FDA approval.
FDA has warned compounders not to use food-grade NAD+ ingredients to make sterile injectable drugs without appropriate processing because of microbial and endotoxin risk.
FDA has received adverse-event reports after injectable NAD+ products, including severe chills, shaking, vomiting and fatigue, with some patients requiring medical treatment.
Practical notes
In a 2026 retrospective commercial-clinic study, IV NAD+ was associated with moderate-to-severe gastrointestinal symptoms, increased heart rate and chest pressure during infusion.
FDA adverse-event reports involving injectable NAD+ include severe chills, shaking, vomiting and fatigue, with some cases requiring medical treatment; FDA said the pattern was consistent with excessive endotoxin exposure.
Sterile compounded products can carry contamination, endotoxin, concentration and source-material risks independent of NAD+'s normal biological role.
Long-term risks and benefits of repeated high-dose IV NAD+ for wellness have not been established in adequately powered controlled trials.
Common mistakes
Treating NAD+ as a peptide because it appears in the same wellness ecosystem.
Using NR or NMN trial results as if they directly prove that IV NAD+ has the same clinical effects.
Assuming that because NAD+ is naturally present in cells, high-dose IV administration is automatically safe or beneficial.
Presenting commercial infusion protocols as evidence-based anti-aging doses.
Using a peptide vial calculator for an IV infusion where rate, sterile formulation and clinical monitoring matter.
Common questions
Is NAD+ a peptide?
No. NAD+ is a small-molecule dinucleotide cofactor, not a peptide. It is included in the library as a related compound because it overlaps heavily with mitochondrial, metabolic and longevity research.
Does IV NAD+ have proven anti-aging benefits?
No. A 2026 systematic review found no eligible IV or intramuscular NAD+ outcomes trials demonstrating anti-aging or wellness benefit.
Are NR and NMN the same as NAD+?
No. NR and NMN are NAD-related precursor compounds. They can affect NAD metabolism, but their human trial results should not be treated as direct evidence for IV NAD+.
Why is there no calculator?
IV NAD+ involves concentration, infusion rate, sterile-product quality and clinical monitoring. The current peptide vial calculator only performs simple vial concentration arithmetic and is not appropriate for this route.
Does 503A Category 1 mean FDA approved?
No. Category 1 means the nominated bulk substance is under FDA evaluation in the 503A compounding process; it is not an approval of NAD+ injection for wellness or any indication.
Related profiles
MOTS-c
Naturally occurring 16-amino-acid mitochondrial-derived peptide studied in metabolic stress, exercise and ageing biology, with no established human therapeutic exposure data.
Open reference →SS-31 / Elamipretide
Mitochondrial cardiolipin-binding tetrapeptide now FDA-approved as Forzinity for improving muscle strength in Barth syndrome patients weighing at least 30 kg.
Open reference →References
NAD+ supplementation for anti-aging and wellness — 2026 systematic review
Ageing Research Reviews / PubMed · 2026
Human plasma and urine NAD+ metabolome during six-hour IV infusion
Frontiers in Aging Neuroscience / PubMed · 2019
IV NAD+ versus IV nicotinamide riboside — retrospective tolerability pilot
PubMed · 2026
FDA reminder on suitable ingredients for sterile NAD+ compounding
U.S. FDA · 2024
FDA 503A bulk substances under evaluation — NAD listed in Category 1
U.S. FDA · 2026
Nicotinamide adenine dinucleotide in ageing biology — critical review
Endocrine Reviews / PubMed · 2023